SEC 13F Intelligence

Managers / Q4 2018 · view latest →

DAFNA Capital Management LLC

CIK 0001389933 · 10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES, CA, 90024 · (310) 954-3200

Reported Value
$201M
Q4 2018
Positions
83
Filings on Record
30
2019–present window
Filed
Feb 14, 2019
original filing

Summary

Dafna Capital Management LLC reported $201M in U.S.-listed holdings across 83 positions for Q4 2018.

Its largest position, Loxo Oncology, represents 12.7% of the portfolio.

Portfolio Metrics

Top-10 Concentration
+47.8%
share of reported value
Largest Position
+12.7%
Loxo Oncology

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $201MQ4 ’18Q1 ’19: $232MQ2 ’19: $266MQ3 ’19: $266MQ4 ’19: $291MQ4 ’19Q1 ’20: $240MQ2 ’20: $347MQ3 ’20: $308MQ4 ’20: $336MQ4 ’20Q1 ’21: $421MQ2 ’21: $478MQ3 ’21: $377MQ4 ’21: $398MQ4 ’21Q1 ’22: $384MQ2 ’22: $367MQ3 ’22: $372MQ4 ’22: $355MQ4 ’22Q1 ’23: $334MQ2 ’23: $366MQ3 ’23: $321MQ4 ’23: $417MQ4 ’23Q1 ’24: $439MQ2 ’24: $419MQ3 ’24: $423MQ4 ’24: $393MQ4 ’24Q1 ’25: $353MQ2 ’25: $362MQ3 ’25: $405MQ4 ’25: $431MQ4 ’25Q1 ’26: $440Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 55.9%Other: 34.5%ADR: 4.7%ETP: 3.1%US DOMESTIC: 1.8%
  • Common Stock · 55.9% · $112M
  • Other · 34.5% · $69M
  • ADR · 4.7% · $9M
  • ETP · 3.1% · $6M
  • US DOMESTIC · 1.8% · $4M

Quarter-over-Quarter Changes full breakdown →

IssuerMoveShare ΔShares nowValue ΔValue now
LOXO ONCOLOGY INCNEW+181.7K181.7K+$25M$25M
RJR1STEREOTAXIS INCNEW+13.68M13.68M+$15M$15M
SG7SAGE THERAPEUTICS INCNEW+104.3K104.3K+$10M$10M
ATRCATRICURE INCNEW+318.7K318.7K+$10M$10M
NXSTAGE MEDICAL INCNEW+312.1K312.1K+$9M$9M
ISHARES TR NASDAQ BIOTECHNEW+64.9K64.9K+$6M$6M
ARGXARGENX SENEW+58.3K58.3K+$6M$6M
ZGNXEURZOGENIX INCNEW+143.8K143.8K+$5M$5M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2018

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1LOXO ONCOLOGY INCCOM12.65%$25M181.7K
2RJR1STEREOTAXIS INChistory →COM7.35%$15M13.68M
3SG7SAGE THERAPEUTICS INChistory →COM4.97%$10M104.3K
4ATRCATRICURE INChistory →COM4.85%$10M318.7K
5NXSTAGE MEDICAL INCCOM4.44%$9M312.1K
6ISHARES TR NASDAQ BIOTECHETF3.11%$6M64.9K
7ARGXARGENX SEhistory →SPONSORED ADR2.79%$6M58.3K
8ZGNXEURZOGENIX INChistory →COM NEW2.61%$5M143.8K
9AERIEURAERIE PHARMACEUTICALS INChistory →COM2.55%$5M141.8K
102655787DBLUEPRINT MEDICINES CORPhistory →COM2.48%$5M92.7K
11ASCENDIS PHARMA A SSPONSORED ADR2.41%$5M77.2K
12PROQR THERAPEUTICS N VSHS EURO2.14%$4M272.5K
13DC4DEXCOM INChistory →COM2.03%$4M34.0K
14ALDR1EURALDER BIOPHARMACEUTICALS INChistory →COM2.02%$4M396.0K
15AKBAAKEBIA THERAPEUTICS INChistory →COM1.97%$4M715.5K
16NBIXNEUROCRINE BIOSCIENCES INChistory →COM1.95%$4M55.0K
17GALAPAGOS NVSPON ADR1.90%$4M41.6K
18BCRXBIOCRYST PHARMACEUTICALS INChistory →COM1.86%$4M464.4K
19ARNAEURARENA PHARMACEUTICALS INChistory →COM NEW1.82%$4M93.9K
20INTEC PHARMA LTD JERUSALEMSHS1.74%$3M463.2K
21LUMINEX CORPCOM1.59%$3M138.4K
22RADIUS HEALTH INCNOTE 3.000% 9/01.52%$3M4.00M
23BIOHAVEN PHARMACEUTICALS HOLDCOM1.47%$3M80.0K
24FOAMIX PHARMACEUTICALS LTDSHS1.44%$3M808.0K
25BLUEBIRD BIO INCCOM1.33%$3M27.0K
26CYMABAY THERAPEUTICS INCCOM1.30%$3M332.5K
27BIOTELEMETRY INCCOM1.27%$3M42.8K
28MNLOUSDMENLO THERAPEUTICS INChistory →COM1.11%$2M540.6K
29KURAKURA ONCOLOGY INChistory →COM1.04%$2M148.6K
30WAVE LIFE SCIENCES LTDSHS1.00%$2M47.9K
31CSIIEURCARDIOVASCULAR SYSTEMS INCCOM0.94%$2M66.2K
32CARA THERAPEUTICS INCCOM0.93%$2M143.6K
33TRANSLATE BIO INCCOM0.85%$2M228.9K
34INSULET CORPNOTE 1.375%0.79%$2M1.50M
35XENEXENON PHARMACEUTICALS INCCOM0.75%$2M237.7K
36VKTXVIKING THERAPEUTICS INCCOM0.68%$1M179.2K
37INCYINCYTE CORPCOM0.68%$1M21.5K
38VAC2USDVBI VACCINES INCCOM NEW0.68%$1M850.0K
39CNCEEURCONCERT PHARMACEUTICALS INCCOM0.66%$1M105.7K
40BABYEURNATUS MEDICAL INCCOM0.64%$1M37.9K
41ARQLUSDARQULE INCCOM0.63%$1M457.7K
42DRNAUSDDICERNA PHARMACEUTICALS INCCOM0.63%$1M118.5K
43NVROEURNEVRO CORPCOM0.60%$1M31.2K
44JNJJOHNSON AND JOHNSONCOM0.60%$1M9.4K
45CYTKCYTOKINETICS INCCOM NEW0.58%$1M185.8K
46IMMUIMMUNOMEDICS INCCOM0.58%$1M82.3K
47ASSEMBLY BIOSCIENCES INCCOM0.57%$1M50.6K
48ACHNEURACHILLION PHARMACEUTICALSCOM0.50%$1M630.2K
49MGNXMACROGENICS INCCOM0.49%$994,00078.3K
50I9DNARBUTUS BIOPHARMA CORPCOM0.47%$946,000246.9K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$440M83May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$431M77Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$405M75Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$362M76Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$353M83May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$393M82Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$423M84Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$419M83Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$439M72May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$417M76Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$321M75Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$366M73Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$334M72May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$355M79Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$372M87Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$367M90Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$384M94May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$398M87Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$377M80Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$478M84Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$421M89May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$336M74Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$308M80Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$347M87Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$240M80May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$291M81Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$266M89Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$266M87Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$232M79May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$201M83Feb 14, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 1 additional manager.

  • Fischel Nathan028-12328

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.